The primary endpoint of this phase II study is to determine the objective response rate
(partial response [PR] + complete response [CR]) of specific pembrolizumab-lenvatinib
combination therapy in patients with locally advanced or metastatic cervical cancer. The
phase II portion of the trial will follow Simon's minimax two-stage design1.
In the Stage 1, 11 patients will be accrued. If 1 or fewer patients among these 11 patients
achieve an objective response with the pembrolizumab-lenvatinib combination therapy, the
combination therapy will be rejected and the trial stopped. However, if there are 2 or more
patients who exhibit response in the Stage 1, then an additional 24 patients will be entered
into the Stage 2, for a total of 35 patients in this phase II study. If 9 or more patients
exhibit response among these 35 patients, then the treatment will be considered for further
investigation. Any unplanned interim analysis will utilize the sequential conditional
probability ratio test (SCPRT)2, which allows an early assessment of statistical evidence for
both efficacy and futility, and provides a discordance probability that early trend could be
reversed should the trial continue to enroll all 35 patients.
1. Female participants who are at least 18 years of age on the day of signing informed
consent with histologically confirmed diagnosis of locally advanced or metastatic
cervical cancer will be enrolled in this study.
2. Patients with progression or intolerance to at least one line of therapy in the
locally advanced or metastatic setting will be eligible for this study.
3. A female participant is eligible to participate if she is not pregnant, not
breastfeeding, and at least one of the following conditions applies:
1. Not a woman of childbearing potential (WOCBP) as defined OR
2. A WOCBP who agrees to follow the contraceptive guidance during the treatment
period and for at least 120 days after the last dose of study treatment.
4. The participant (or legally acceptable representative if applicable) provides written
informed consent for the trial.
5. Have measurable disease based on RECIST 1.1. Lesions situated in a previously
irradiated area are considered measurable if progression has been demonstrated in such
6. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE)
tissue blocks are preferred to slides. Newly obtained biopsies are preferred to
archived tissue. Note: If submitting unstained cut slides, newly cut slides should be
submitted to the testing laboratory within 14 days from the date slides are cut.
7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Evaluation of ECOG is to be performed within 28 days prior to the date of treatment
8. Have adequate organ function as defined. Specimens must be collected within 28 days
prior to the start of study treatment.
1. Absolute neutrophil count (ANC) ≥1500/µL
2. Platelets ≥100 000/µL
3. Hemoglobin ≥9.0 g/dL
4. Creatinine OR Measured or calculated creatinine clearance (GFR can also be used
in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with
creatinine levels >1.5 × institutional ULN
5. Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total
bilirubin levels >1.5 × ULN
6. AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver
7. International normalized ratio (INR) OR prothrombin time (PT), Activated partial
thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving
anticoagulant therapy as long as PT or aPTT is within therapeutic range of
intended use of anticoagulants
1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment
initiation. If the urine test is positive or cannot be confirmed as negative, a serum
pregnancy test will be required.
2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent.
3. Has received prior systemic anti-cancer therapy including investigational agents
within 4 weeks Note: Participants must have recovered from all AEs due to previous
therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be
eligible.Note: If participant received major surgery, they must have recovered
adequately from the toxicity and/or complications from the intervention prior to
starting study treatment.
4. Has received prior radiotherapy within 2 weeks of start of study treatment.
Participants must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system
5. Has received a live vaccine or live attenuated vaccine within 30 days prior to the
first dose of study drug. Administration of killed vaccines is allowed.
6. Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
8. Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years. Note: Participants with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma) that
have undergone potentially curative therapy are not excluded.
9. Has known active CNS metastases and/or carcinomatous meningitis. Participants with
previously treated brain metastases may participate provided they are radiologically
stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging
(note that the repeat imaging should be performed during study screening), clinically
stable and without requirement of steroid treatment for at least 14 days prior to
first dose of study treatment.
10. Has severe hypersensitivity (≥Grade 3) to pembrolizumab or lenvatinib and/or any of
11. Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
12. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease.
13. Has an active infection requiring systemic therapy.
14. Has a known history of Human Immunodeficiency Virus (HIV).
15. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is
detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required
unless mandated by local health authority.
16. Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
17. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
18. Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment.
19. Has uncontrolled blood pressure (BP) (Systolic BP>140 mmHg or diastolic BP>90 mmHg) in
spite of an optimized regimen of antihypertensive medication.
20. Has electrolyte abnormalities that have not been corrected.
21. Has significant cardiovascular impairment: history of congestive heart failure greater
than New York Heart Association (NYHA) Class II, unstable angina, myocardial
infarction or stroke within 6 months of the first dose of study drug, or cardiac
arrhythmia requiring medical treatment at Screening.
22. Has bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The
degree of tumor invasion/infiltration of major blood vessels (e.g. carotid artery)
should be considered because of the potential risk of severe hemorrhage associated
with tumor shrinkage/necrosis following lenvatinib therapy.
23. Subjects having > 1+ proteinuria on urine dipstick testing unless a 24-hour urine
collection for quantitative assessment indicates that the urine protein is <1 g/24
24. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other
condition that might affect the absorption of lenvatinib.
25. Prolongation of QTc interval to >480 ms.